<DOC>
	<DOCNO>NCT00098995</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , tirapazamine cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Tirapazamine may help cisplatin kill tumor cell make tumor cell sensitive drug . Radiation therapy use high-energy x-ray kill tumor cell . Tirapazamine may also make tumor cell sensitive radiation therapy . Giving radiation therapy different way together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose tirapazamine give together cisplatin radiation therapy treat patient stage IB , stage II , stage III , stage IVA cervical cancer .</brief_summary>
	<brief_title>Tirapazamine , Cisplatin , Radiation Therapy Treating Patients With Stage IB , Stage II , Stage III , Stage IVA Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II III dose tirapazamine combine cisplatin radiotherapy patient Stage IB-IVA squamous cell carcinoma , adenocarcinoma , adenosquamous cell carcinoma cervix . - Determine safety tolerability regimen patient . Secondary - Determine failure-free survival patient treat regimen . - Determine overall survival patient treat regimen . - Determine time locoregional failure patient treat regimen . - Determine pattern failure site first failure patient treat regimen . - Determine 12-week post-treatment complete response rate patient treat regimen . OUTLINE : This multicenter , dose-escalation study tirapazamine . Patients receive tirapazamine IV 2 hour day 1 week 1-5 day 3 5 week 1 2 ( cohort 2 ) , OR day 3 5 week 1-4 ( cohort 3 ) . Patients also receive cisplatin IV 1 hour day 1 week 1-6 . Patients concurrently undergo external beam radiotherapy daily day 1-5 5-5.5 week . After completion chemoradiotherapy , patient undergo low-dose brachytherapy ( 2 implant within 8-week period ) OR high-dose brachytherapy twice weekly 5 treatment . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tirapazamine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 10 patient treated MTD . Patients follow 2 , 4 , 8 week , 3 6 month , every 3 month 2 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 3-22 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma , adenocarcinoma , adenosquamous cell carcinoma cervix Stage IB , IIA , IIB , III , IVA disease No evidence involvement paraaortic node CT scan , MRI , fluorodeoxyglucose positron emission tomography , lymphadenectomy Involvement common iliac node allow No evidence distant metastasis PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 02 Life expectancy More 6 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 1.25 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Renal Calculated creatinine clearance ≥ 60 mL/min OR Glomerular filtration rate ≥ 60 mL/min Cardiovascular No significant cardiac disease would preclude IV fluid load require administration cisplatin No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other No symptomatic peripheral neuropathy ≥ grade 2 No clinically significant sensorineural hearing impairment interfere activity daily live require hear aid Audiometric change alone severity allow No history allergic reaction attribute compound similar chemical biological composition tirapazamine cisplatin No invasive malignancy within past 5 year except nonmelanoma skin cancer No ongoing active infection No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent epoetin alfa No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent pegfilgrastim Chemotherapy No prior chemotherapy another malignancy Endocrine therapy Not specify Radiotherapy No prior pelvic abdominal radiotherapy another malignancy No prior radiotherapy ≥ 15 % bone marrowbearing area No concurrent intensitymodulated radiotherapy No concurrent interstitial brachytherapy Surgery Not specify Other No prior treatment invasive cervical cancer No concurrent therapeutic investigational agent No concurrent anticancer therapy No concurrent systemic retinoids No concurrent amifostine No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>